| |  Online-Ressource |
|---|
| Verfasst von: | Robinson, Stephen [VerfasserIn]  |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| | Caballero, D. [VerfasserIn] |
|---|
| | Corradini, P. [VerfasserIn] |
|---|
| | Geisler, C. [VerfasserIn] |
|---|
| | Ghielmini, M. [VerfasserIn] |
|---|
| | Le Gouill, S. [VerfasserIn] |
|---|
| | Kimby, E. [VerfasserIn] |
|---|
| | Rule, S. [VerfasserIn] |
|---|
| | Vitolo, U. [VerfasserIn] |
|---|
| | Dreyling, M. [VerfasserIn] |
|---|
| | Hermine, O. [VerfasserIn] |
|---|
| Titel: | The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma |
|---|
| Verf.angabe: | S. Robinson, P. Dreger, D. Caballero, P. Corradini, C. Geisler, M. Ghielmini, S. Le Gouill, E. Kimby, S. Rule, U. Vitolo, M. Dreyling and O. Hermine on behalf of the European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
|---|
| E-Jahr: | 2015 |
|---|
| Jahr: | [2015] |
|---|
| Jahr des Originals: | 2014 |
|---|
| Umfang: | 10 S. |
|---|
| Illustrationen: | Diagramme |
|---|
| Fussnoten: | Advance online publication: 29 August 2014 ; Gesehen am 02.07.2020 |
|---|
| Titel Quelle: | Enthalten in: Leukemia |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2015 |
|---|
| Band/Heft Quelle: | 29(2015), 2, Seite 464-473 |
|---|
| ISSN Quelle: | 1476-5551 |
|---|
| Abstract: | The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND-modified Delphi consensus procedure to provide guidance on how SCT should be used in MCL. With regard to autoSCT, there was consensus in support of: autoSCT is the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; complete or partial remission should be achieved before autoSCT; Rituximab maintenance following autoSCT is not indicated; and omission of autoSCT in ‘low-risk’ patients is not indicated. No consensus could be reached regarding: autoSCT in the treatment of relapsed disease following non-transplant therapy; the value of positron emission tomography scanning and minimal residual disease (MRD) monitoring; in vivo purging with Rituximab; total body irradiation conditioning for autoSCT; and preemptive Rituximab after autoSCT. For alloSCT, consensus was reached in support of: alloSCT should be considered for patients relapsing after autoSCT; reduced intensity conditioning regimens should be used; allogeneic immunotherapy should be used for MRD eradication after alloSCT; and there is a lack of prognostic criteria to guide the use of alloSCT as first-line consolidation. No consensus was reached regarding the role of alloSCT for relapsed disease following non-transplant therapy. |
|---|
| DOI: | doi:10.1038/leu.2014.223 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/leu.2014.223 |
|---|
| | Volltext: https://www.nature.com/articles/leu2014223 |
|---|
| | DOI: https://doi.org/10.1038/leu.2014.223 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1703212436 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬The¬ EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma / Robinson, Stephen [VerfasserIn]; [2015] (Online-Ressource)
